CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences Inc. (NASDAQ: ENVB), a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics, has announced new data regarding its lead development candidate, EB-003. The data reveals that EB-003 acts as an agonist of the serotonin receptor 5-HT1B, a validated target for drugs treating major depressive disorder and various neurological conditions such as Parkinson's disease, migraines, and cluster headaches. These results, which add to existing evidence of EB-003's receptor engagement activities, were presented by the company. The study highlighted EB-003's potential to elicit neuroplastogenic effects without adverse hallucinogenic outcomes, broadening its clinical indication potential. Enveric Biosciences plans to continue IND-enabling activities for EB-003 through 2025, as part of its strategy to explore therapeutic opportunities in psychiatric and neurological markets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.